Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 1/20 | 0.41 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 3/20 | 0.41 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.40 |
| ▸ | FABP7 | O15540 | 2/20 | 0.40 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19927592 | 1.00 | AGTR2 (0.41) | AGTR2ACEPOLBFABP5FABP7 | |
| SCHEMBL31369964 | 0.96 | ACE (0.41) | ACEPOLBFABP5FABP7MDM4 | |
| SCHEMBL31369965 | 0.96 | ACE (0.41) | ACEPOLBFABP5FABP7MDM4 | |
| SCHEMBL29400546 | 0.88 | ACE (0.52) | ACEPOLBFABP5FABP7TDP1 | |
| SCHEMBL119605 | 0.88 | ACE (0.52) | ACEPOLBFABP5FABP7TDP1 | |
| SCHEMBL119635 | 0.88 | ACE (0.52) | ACEPOLBFABP5FABP7TDP1 | |
| SCHEMBL13252698 | 0.88 | ACE (0.52) | ACEPOLBFABP5FABP7TDP1 | |
| SCHEMBL29398714 | 0.88 | ACE (0.52) | ACEPOLBFABP5FABP7TDP1 | |
| SCHEMBL31370192 | 0.88 | POLB (0.49) | AGTR2ACEPOLBFABP5FABP7 | |
| SCHEMBL31369622 | 0.86 | OPRM1 (0.45) | AGTR2ACEPOLBFABP5TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3507275-B1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | RECEPTOS LLC | 2019-11-14 | — | — | US | disclosed |
| EP-3507275-A1 | CXCR3 RECEPTOR AGONISTS | Celgene International II Sarl (CH) | 2019-07-10 | — | — | EP | disclosed |
| WO-2018045246-A1 | CXCR3 RECEPTOR AGONISTS | CELGENE INTERNATIONAL II SARL (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11040954-B1 | CXCR3 receptor agonists | CXCR3, CXCR1, CCR7 | AGTR2 319/4885ACE 4630/4885POLB 2573/4885 |
| US-20190345133-A1 | CXCR3 RECEPTOR AGONISTS | CXCR3, CXCR1, CCR7 | AGTR2 319/4885ACE 4630/4885POLB 2573/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.